Tonix Pharmaceuticals Holding Corp. (TNXP) is a biotherapeutics company engaged in the discovery, licensing, acquisition, and development of therapeutics for different diseases. The company’s product pipeline consists of TNX-1800 as a COVID-19 vaccine. TNX-3500 and TNX-102 SL are under the clinical stage for treating COVID-19. TNX-102 SL is the company’s CNS candidate in Phase 3 trials for treating fibromyalgia. TNX-1300 is used to treat cocaine intoxication.
The price of TNXP stock during the regular trading on February 7, 2022, was $0.23 with an incline of 6.65%. At last check in the premarket on February 8, 2022, the stock dropped by 3.87%.
TNXP: Events and Happenings
On February 07, 2022, New to the Street TV updated about interviewing TNXP’s CEO Seth Lederman on the same date. The host and guest discussed the company’s Covid-19 vaccine, antiviral pharmaceutical, and COVID-related innovative product line. On February 07, 2022, TNXP was informed about attending the Virtual BIO CEO & Investor Conference by its Executive management. The conference will be held on February 14-17, 2022.
On January 11, 2022, TNXP reported about the preliminary patient enrollment in the dose-finding trials for TNX-2100. It is used to measure delayed-type hypersensitivity (DTH) to CoV-2. On January 05, 2022, TNXP announced that the Executive management of the company participated in the following conferences.
- Virtual H.C. Wainwright BioConnect Conference on January 10-13, 2022.
- The Virtual Biotech Showcase 2022 was held on January 10-12, 2022.
On January 04, 2022, TNXP was informed about the research partnership and options contract with Kansas State University. Both parties agreed upon the development of zinc nanoparticle mRNA vaccines to replace the lipid-nanoparticle technology. The ZNP technology conferred augmented stability to mRNA vaccination over a wide temperature range. On December 15, 2021, TNXP was added to the Nasdaq Biotechnology Index with effect from December 20, 2021.
TNXP: Key Financials
On November 8, 2021, TNXP released its financial results for the third quarter of 2021 ended September 30, 2021. Some of the key highlights are mentioned below.
Assets
Total current assets in Q3 2021 were recorded to be $195 million.
EPS
Basic and diluted net loss per share in Q3 2021 was $18.5 million or $0.05 compared to $11.9 million, or $0.09 in the same period of 2020. The company’s EPS beat the analyst’s estimate by $0.02.
Conclusion
TNXP’s stock downplayed by 66% from the last six months period due to financial restrains by the pandemic. The company’s stock declined in the current premarket despite the fact that the company announced a special stockholders meeting and its interview being featured on the New to the Street TV. As TNXP is approaching its earning release date, the analysts are predicting the current quarter’s EPS to be -$0.05.
